Solopharm's brand, Oxyfrin, has been nominated for the professional «XXVI Platinum Ounce» award in the «Drug of the Year. Launch of the Year. Retail Segment» category, following the first round of voting.
The «Platinum Ounce» is one of the most prestigious professional awards in the Russian pharmaceutical market, annually bringing together industry experts, representatives from pharmaceutical companies, distributors, pharmacy chains, and the medical community. In the first stage of voting, the award's expert council creates a shortlist of drugs that have had the greatest impact on market development and clinical practice.
The awards ceremony and the announcement of the winners will take place on April 16th in Moscow. The event will be held in person and broadcast to a wide professional audience across all regions of Russia.
The second stage of voting will last until March 31, 2026.
Oxyfrin is a modern medication for the treatment of rhinitis symptoms, based on oxymetazoline, developed in accordance with current clinical recommendations and patient needs. The brand's inclusion among the award nominees confirms the high level of interest from the professional community and the product's significance for the retail segment of the pharmaceutical market.
The «Platinum Ounce» award ceremony is traditionally one of the key industry events of the year and is widely covered by professional, business, and public media. The award serves as a platform for recognizing the achievements of companies and products that are shaping the future of the pharmaceutical industry.
Comment from the Solopharm Press Center:
«For us, the nomination of Oxyfrin for the «Platinum Ounce» award is an important professional recognition of our team's work. We consistently invest in the development of high-quality and accessible medications and value the attention of industry experts to our products».
